Allelic and genotype frequencies of catechol-o-methyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the philippines

International Journal of Molecular Epidemiology and Genetics

Volumn 3, Issue 2, 2012, Pages 115-121

  Baclig, Michael O ^a   Predicala, Rey Z ^a   Mapua, Cynthia A ^a   Lozano Kühne, Jingky P ^a   Daroy, Maria Luisa G ^a   Natividad, Filipinas F ^a   Javier, Francis O ^a  

^a ST LUKE S MEDICAL CENTER   (Philippines)

Author keywords

Allele frequency; Catechol o methyltransferase; Cyp2d6*10; Filipino; Polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHILIPPINES; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 84861769282     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D. COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science 2003; 299: 1240-1243.
2. Rakvåg TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F. The val158met polymorphism of the human cate-chol-O-methyltransferase gene may influence morphine requirements in cancer pain patients. Pain 2005; 116: 73-78.
3. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005; 14: 135-143.
4. Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008; 4: 64.
5. Ji L, Pan S, Marti-Jaun J, Hänseler E, Rentsch K, Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in Mainland Chinese. Clin Chem 2002; 48: 983-988.
6. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 2006; 34: 563-569.
7. Von Ahsen N, Tzvetkov M, Karunajeewa HA, Gomorrai S, Ura A, Brockmöller J, Davis TM, Mueller I, Ilett KF, Oellerich M. CYP2D6 and CYP2C19 in Papua New Guinea: high frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. Int J Mol Epidemiol Genet 2010; 1: 310-319.
8. Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62: 927-931.
9. Cai WM, Chen B, Zhang WX. Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clin Pharmacol Ther 2007; 81: 95-98.
10. Inoue H, Shibuta K, Matsuyama A, Yoshinaga K, Sadanaga N, Ueo H, Barnard GF, Mori M. Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer. Oncol Rep 2005; 14: 707-712.
11. Theophilus NA, Chandrasekaran A, Sam SS, Gerard N, Rajagopal K. CYP2D6 genetic poly morphism in South Indian populations. Biol Pharm Bull 2006; 29: 1655-1658.
12. Hu Z, Song CG, Lu JS, Luo JM, Shen ZZ, Huang W, Shao ZM. A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha COMT and CYP19 gene in BRCA1/ BRCA2 negative Shanghai women with early onset breast cancer or affected relatives. J Cancer Res Clin Oncol 2007; 133: 969-978.
13. Tanaka Y, Hirata H, Chen Z, Kikuno N, Kawamoto K, Majid S, Tokizane T, Urakami S, Shiina H, Nakajima K, Dhir R, Dahiya R. Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Cancer Epidemiol Bio-markers Prev 2007; 16: 92-97.
14. Lim JH, Kim SY, Kim do J, Park SY, Han HW, Han JY, Lee SW, Yang JH, Ryu HM. Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17α in preeclampsia. Phar-macogenet Genomics 2010; 20: 605-610.
15. Fontana L, Delort L, Joumard L, Rabiau N, Bos-viel R, Satih S, Guy L, Boiteux JP, Bignon YJ, Chamoux A, Bernard-Gallon DJ. Genetic polymorphisms in CYP1A1 CYP1B1 COMT GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res 2009; 29: 1631-1635.
16. Fiocco AJ, Lindquist K, Ferrell R, Li R, Simonsick EM, Nalls M, Harris TB, Yaffe K. Health ABC Study. COMT genotype and cognitive function: an 8-year longitudinal study in white and black elders. Neurology 2010; 74: 1296-1302.
17. Schmahl C, Ludäscher P, Greffrath W, Kraus A, Valerius G, Schulze TG, Treutlein J, Rietschel M, Smolka MN, Bohus M. COMT val158met polymorphism and neural pain processing. PLoS One 2012; 7: e23658.
18. Jensen KB, Lonsdorf TB, Schalling M, Kosek E, Ingvar M. Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val158met polymorphism. PLoS One 2009; 4: e6016.
19. Wang SL, Lai MD, Huang JD. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab Dispos 1999; 27: 385-388.
20. Lee EJD, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994; 37: 605-607.
21. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Ka-mataki T, Kobayashi. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999; 65: 570-575.
22. Garcia-Barceló M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, Waye MM. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 2000; 46: 18-23.
23. Lee SJ, Lee SS, Jung HJ, Kim HS, Park SJ, Yeo CW, Shin JG. Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab Dispos 2009; 37: 1464-1470.
24. Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001; 26: 205-211.
25. Suwannasri P, Thongnoppakhun W, Pramyothin P, Assawamakin A, Limwongse C. Combination of multiplex PCR and DHPLC-based strategy for CYP2D6 genotyping scheme in Thais. Clin Bio-chem 2011; 44: 1144-1152.
26. Wan YJ, Poland RE, Han G, Konishi T, Zheng YP, Berman N, Lin KM. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California. Pharma-cogenetics 2001; 11: 489-499.
27. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of de-brisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441-446.
28. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cyto-chrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999; 9: 669-682.
29. Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles their frequencies and evolution. Pharmacogenetics 1997; 7: 193-202.
30. Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, Lin KM. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 2001; 70: 552-560.
31. Ramamoorthy Y, Tyndale RF, Sellers EM. Cyto-chrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 2001; 11: 477-487.
32. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221.
33. Stamer UM, Stüber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 2007; 20: 478-484.
34. Kim H, Dionne RA. Individualized pain medicine. Drug Discov Today Ther Strateg 2009; 6: 83-87.
35. Yu KD, Shao ZM. Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms. Nat Rev Cancer 2009; 9: 576-586.